Meeting
2018 Genitourinary Cancers Symposium
Extended radical prostatectomy following neoadjuvant chemohormononal therapy (low dose estrmustine + LHRH agonist/antagonist) contributes to good cancer control for patients with high risk localized prostate cancer.
Authors
Hideki Enokida
Kagoshima University Graduate of School of Medical and Dental Sciences, Kagoshima, Japan
Hideki Enokida , Hirofumi Yoshino , Masayuki Nakagawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 185)
DOI
10.1200/JCO.2018.36.6_suppl.185
Abstract #
185
Poster Bd #
J5
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Clinical characteristics and treatment patterns of patients with high-risk localized prostate cancer (HR LPC) treated with radical prostatectomy (RP) and perioperative hormonal therapy (HT) in Japan, South Korea, and Taiwan.
First Author: Shingo Hatakeyama
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant pamiparib plus abiraterone and ADT for high-risk/very high-risk localized prostate cancer: Results of a prospective study.
First Author: Junlong Zhuang
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial.
First Author: Junlong Zhuang
Poster
2023 ASCO Genitourinary Cancers Symposium
Length and Gleason pattern at positive surgical margin after radical prostatectomy to assess risk of postoperative recurrence in localized prostate cancer.
First Author: Masashi Kato